Clinical Trials Logo

Mutation clinical trials

View clinical trials related to Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04983628 Active, not recruiting - Clinical trials for Prostate Cancer Metastatic

Molecular Profiling in Prostate Cancer

ProProstate
Start date: October 1, 2020
Phase:
Study type: Observational

We aim to employ targeted DNA NGS to evaluate the prevalence of germline and somatic mutations in cancer predisposing genes, such as BRCA1 and BRCA2, and other HR and DDR genes, including also a few additional clinically relevant genes, in patients with metastatic, locally advanced or high-grade prostate cancer. In addition, we will investigate the prognostic role of these mutations as well as their association with various clinicopathological parameters. This will be the first study investigating the prevalence of germline and somatic pathogenic mutations in Greek patients with prostate cancer.

NCT ID: NCT03857594 Active, not recruiting - Mutation Clinical Trials

Integrative Sequencing In Germline and Hereditary Tumours

INSIGHT
Start date: October 2, 2018
Phase:
Study type: Observational

This study will investigate the utility of integrative sequencing of individuals and families at risk of hereditary cancer syndromes and will uncover novel contributors to tumourigenesis. Integrative sequencing refers to: 1. Whole genome sequencing (WGS) of the germline (inherited) genome 2. Whole exome sequencing (WES) or targeted/panel sequencing of tumour(s) (somatic, tumour-specific mutations) 3. DNA methylation (methylome) analysis of tumour(s) 4. RNA sequencing (transcriptome) of tumour(s) Eligible patients receiving genetic care at Princess Margaret Cancer Centre and the University Health Network may be approached by their genetic counsellor for participation in this study.